Wall Street analysts expect Walgreens Boots Alliance (WBA) to post quarterly earnings of $0.37 per share in its upcoming report, which indicates a year-over-year decline of 43.9%. Revenues are expected to be $37.1 billion, up 1.1% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.7% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Walgreens metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts forecast 'Revenues- U.S. Retail Pharmacy' to reach $29.19 billion. The estimate indicates a change of +0.9% from the prior-year quarter.
Analysts predict that the 'Revenues- International' will reach $5.91 billion. The estimate indicates a change of +1.4% from the prior-year quarter.
The consensus estimate for 'Revenues- U.S. Healthcare' stands at $2.04 billion. The estimate suggests a change of +5.9% year over year.
According to the collective judgment of analysts, 'Revenues- U.S. Retail Pharmacy- Pharmacy' should come in at $23.15 billion. The estimate points to a change of +3.4% from the year-ago quarter.
Analysts' assessment points toward 'Revenues- U.S. Retail Pharmacy- Retail' reaching $6.31 billion. The estimate indicates a year-over-year change of -3.9%.
The combined assessment of analysts suggests that 'Adjusted operating income (loss)- U.S. Retail Pharmacy' will likely reach $298.78 million. The estimate is in contrast to the year-ago figure of $694 million.
Based on the collective assessment of analysts, 'Adjusted operating income (loss)- International' should arrive at $165.99 million. The estimate compares to the year-ago value of $142 million.
View all Key Company Metrics for Walgreens here>>>
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWalgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
